On May 18, 2017 Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, reported that two abstracts on luspatercept will be presented at the 22nd Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) in Madrid, Spain on June 22-25, 2017 (Press release, Acceleron Pharma, MAY 18, 2017, View Source [SID1234519208]). Luspatercept is being developed as part of the global collaboration between Acceleron and Celgene. Schedule your 30 min Free 1stOncology Demo! The oral and poster presentations will include efficacy, duration of response, and long-term safety results from the ongoing Phase 2 studies with luspatercept in myelodysplastic syndromes (MDS) and beta-thalassemia. The presentations at the conference will include updated information beyond that included in the abstracts available online on the EHA (Free EHA Whitepaper) conference website. The beta-thalassemia presentation will review results updated from the ASH (Free ASH Whitepaper) 2016 presentation in December and the MDS presentation will highlight results updated from the recent International Symposium on MDS earlier this month.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral presentation
Title: Luspatercept Increases Hemoglobin and Decreases Transfusion Burden in Adults with Beta-Thalassemia (Abstract: S129)
Session: Thalassemia
Date: Friday, June 23rd
Time: 11:45 a.m. CEST (IFEMA, Room N105)
Poster presentation
Title: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with
Lower-Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study (Abstract: P666)
Session: Myelodysplastic Syndromes – Clinical 2
Date: Saturday, June 24th
Time: 5:30 – 7:00 p.m. CEST (IFEMA, Poster Area, Hall 7)
The luspatercept clinical poster and slides from the oral presentation will be available immediately following the presentations at the conference in the "Science" section on Acceleron’s website, www.acceleronpharma.com.
About Luspatercept
Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members in the transforming growth factor-beta superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoiesis stimulating agents (ESAs), which stimulate the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Phase 3 clinical trials are underway to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the "MEDALIST" study) and in patients with beta-thalassemia (the "BELIEVE" study). For more information, please visit www.clinicaltrials.gov.